RxDoctor Payments Data

Jonathan McFadyen, NP

Nurse Practitioner · Bend, ORNPI 1003136334

Payments from drug & device makers

$423in general payments, 2019–2025

Across 16 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$173
  • United Therapeutics Corporation$39
  • Actelion Pharmaceuticals US, Inc.$37
  • AstraZeneca$33
  • Insmed, Inc.$32
  • Boehringer Ingelheim$30
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$39092%
  • Education$328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 85th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$410,450
Medicare patients
977
Services billed
8,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter445$393,107
OfevNintedanib Esylate20$267,644
Spiriva RespimatTiotropium Bromide72$59,524
Breo ElliptaFluticasone/Vilanterol84$51,652
Stiolto RespimatTiotropium Br/Olodaterol Hcl51$47,668
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$32,141
Spiriva HandihalerTiotropium Bromide23$22,145
Fluticasone-VilanterolFluticasone/Vilanterol69$17,758
Incruse ElliptaUmeclidinium Bromide33$14,949
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,302
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate73$12,835
Arnuity ElliptaFluticasone Furoate39$11,841
Albuterol Sulfate HfaAlbuterol Sulfate324$10,064
DuleraMometasone/Formoterol21$10,021
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$9,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$15$503,690653 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$30$374,836143 claims
AstraZenecaBreztri Aerosphere, Symbicort$33$21,05934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →